Resources for Patients and their Families

Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma

Brief Summary

The main objective of the trial is to document the progression free survival (PFS) in advanced or metastatic malignant pleural mesothelioma patients treated with NGR-hTNF as single agent.

Safety will be established by clinical and laboratory assessment according to NCI-CTC criteria.

Tracking Information
First Received DateJune 7, 2007
Last Changed DateJanuary 14, 2019
Start DateMay 2007
Actual Primary Completion DateMarch 2013
Primary Outcome Measures

Antitumor activity defined as progression free survival (PFS) [Time Frame: during the study]

Secondary Outcome Measures

Tumor Growth Control Rate (TGCR) [Time Frame: Every 6 weeks during study treatment and every 6 weeks during the follow-up before PD]

Overall survival (OS) [Time Frame: from the randomization until to the date of patient death or discontinuation from the study]

Experimental Imaging Study (DCE-MRI) [Time Frame: During the treatment]

Cmax of NGR-hTNF in patients treated with weekly schedule [Time Frame: During the treatment]

AUC(tau) of NGR-hTNF in patients treated with weekly schedule [Time Frame: During the treatment]

Safety according to NCI-CTCAE criteria (version 3) [Time Frame: During the treatment and during the follow-up]

Descriptive Information
PhasePhase 2
Study TypeInterventional
  • Malignant Pleural Mesothelioma
  • Drug: NGR-hTNF
Study Arms / Comparison Groups1 / 0
Detailed Description

This is a phase II, open-label, non-randomized study that will be conducted in patients affected by advanced or metastatic malignant pleural mesothelioma previously treated with no more than one systemic therapeutic regimen , that will be conducted using Simon's two-stage design method.

Recruitment Information
Recruitment StatusCompleted
Actual Enrollment57
Ages18 Years - N/A
Accepts Healthy VolunteersNo
Eligibility Criteria

Inclusion Criteria:

- Patients >18 years affected by malignant pleural mesothelioma previously treated with no more than one systemic therapeutic regimen

- Histologically or cytological confirmed malignant pleural mesothelioma of any of the following subtype: epithelial, sarcomatous, mixed

- Prior intrapleural cytotoxic agents including bleomycin not considered systemic chemotherapy

- ECOG Performance status 0 - 2

- Adequate baseline bone marrow, hepatic and renal function, defined as follows:

- Neutrophils > 1.5 x 10^9/L and platelets > 100 x 10^9/L

- Bilirubin < 1.5 x ULN

- AST and/or ALT < 2.5 x ULN in absence of liver metastasis

- AST and/or ALT < 5 x ULN in presence of liver metastasis

- Serum creatinine < 1.5 x ULN

- Absence of any conditions in which hypervolemia and its consequences (e.g. increased stroke volume, elevated blood pressure) or haemodilution could represent a risk for the patient (take as reference "Technical data sheet human albumin" specifically used in Pharmacy Department for NGR-hTNF dilution)

- Patients may have had prior therapy providing the following conditions are met:

- Chemotherapy and radiotherapy: wash-out period of 28 days

- Surgery: wash-out period of 14 days

- Normal cardiac function and absence of uncontrolled hypertension

- Patients must give written informed consent to participate in the study

Exclusion Criteria:

- Concurrent anticancer therapy

- Patients may not receive any other investigational agents while on study

- Clinical signs of CNS involvement

- Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol

- Known hypersensitivity/allergic reaction to human albumin preparations or to any of the excipients

- Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol

- Pregnancy or lactation. Patients - both males and females - with reproductive potential (i.e. menopausal for less than 1-year and not surgically sterilized) must practice effective contraceptive measures throughout the study. Women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration

Administrative Information
Responsible PartySponsor
SponsorMolMed S.p.A.
Verification DateJanuary 2019
Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: